Search Results

Wren Laboratories, a leader in novel in-vitro diagnostic technologies, announced significant enhancements to its executive leadership team.

Wren Therapeutics announced today that the company has changed its name to WaveBreak.

Wren Therapeutics announced a number of new members to its Scientific Advisory Board.

The presentation will focus on the use of mRNA in Liquid Biopsies as a platform for precision diagnostics

Wren announced today the presentation of preclinical data for its first-in-class, oral inhibitors of α-synuclein oligomer generation demonstrating potent inhibition of both oligomer production and aggregate formation in cell and mouse models used for studying Parkinson’s disease progression.

Wren Therapeutics, a biopharmaceutical company transforming drug discovery for neurodegenerative diseases, announced the appointment of Bart Henderson as Chief Executive Officer.

Wren Therapeutics announced today a number of senior leadership appointments as the company advances its first investigational therapies toward the clinic, based on the company’s breakthrough approach to discovering small molecules that precisely target and shut down the sources of oligomer and aggregate generation in neurodegenerative diseases.

Neuroendocrine Cancer treatment response test, PPQ, delivers 96% accuracy

With NETest, oncologists at leading cancer centers around the globe have a highly accurate molecular diagnostic to add to their patient care arsenal.

Wren Therapeutics Ltd., a biopharmaceutical company pioneering a unique network kinetics approach to drug discovery for protein misfolding diseases, announced the closing of a £12.4 million financing.